Seeking Alpha
Research analyst, IPOs, long/short equity
Profile| Send Message|
( followers)  

The following IPOs are expected to price this week:

500.com (NYSE:WBAI), a leading online sports lottery service provider in China, plans to raise $58 million by offering 5.8 million shares at a price range of $9.00 to $11.00. At the midpoint of the proposed range, 500.com would command a market value of $351 million. 500.com, which was founded in 2001, booked $33 million in sales over the last 12 months. The Shenzhen, China-based company plans to list on the NYSE under the symbol WBAI. Deutsche Bank is the lead bookrunner on the deal.

Evogene (NYSE:EVGN), which develops genetically enhanced seeds to elevate crop performance and productivity, plans to raise $86 million by offering 5.0 million shares at a price of $17.16. At the midpoint of the proposed range, Evogene would command a market value of $412 million. Evogene, which was founded in 2000, booked $18 million in sales over the last 12 months. The Rehovot, Israel-based company plans to list on the NYSE under the symbol EVGN. Credit Suisse and Deutsche Bank are the joint bookrunners on the deal.

GFI Software (Pending:GFIS), which provides collaboration and remote IT management software to small businesses, plans to raise $79 million by offering 6.1 million shares at a price range of $12.00 to $14.00. At the midpoint of the proposed range, GFI Software would command a market value of $557 million. GFI Software, which was founded in 1999, booked $152 million in sales over the last 12 months. The Luxembourg-based company plans to list on the NYSE under the symbol GFIS. J.P. Morgan, Credit Suisse and Jefferies & Co. are the joint bookrunners on the deal.

Navigator Holdings (NYSE:NVGS), which owns and operates the world's largest fleet of handysize liquefied gas carriers, plans to raise $203 million by offering 11.3 million shares at a price range of $17.00 to $19.00. At the midpoint of the proposed range, Navigator Holdings would command a market value of $983 million. Navigator Holdings, which was founded in 1997, booked $207 million in sales over the last 12 months. The London-based company plans to list on the NYSE under the symbol NVGS. Jefferies & Co. and Morgan Stanley are the joint bookrunners on the deal.

Oxford Immunotec Global (NASDAQ:OXFD), which sells diagnostic tests for latent tuberculosis infection, plans to raise $75 million by offering 5.4 million shares at a price range of $13.00 to $15.00. At the midpoint of the proposed range, Oxford Immunotec Global would command a market value of $247 million. Oxford Immunotec Global, which was founded in 2002, booked $34 million in sales over the last 12 months. The Abingdon, United Kingdom-based company plans to list on the NASDAQ under the symbol OXFD. J.P. Morgan and Piper Jaffray are the joint bookrunners on the deal.

Sungy Mobile (NASDAQ:GOMO), which provides mobile apps, literary content and entertainment services for Android, plans to raise $74 million by offering 7.0 million shares at a price range of $9.50 to $11.50. At the midpoint of the proposed range, Sungy Mobile would command a market value of $365 million. Sungy Mobile, which was founded in 2003, booked $47 million in sales over the last 12 months. The Guangzhou, China-based company plans to list on the NASDAQ under the symbol GOMO. Credit Suisse and J.P. Morgan are the joint bookrunners on the deal.

TetraLogic Pharmaceuticals (NASDAQ:TLOG), which is developing small molecule therapeutics for the treatment of cancer, plans to raise $90 million by offering 6.4 million shares at a price range of $13.00 to $15.00. At the midpoint of the proposed range, TetraLogic Pharmaceuticals would command a market value of $270 million. TetraLogic Pharmaceuticals, which was founded in 2001, booked $0 million in sales over the last 12 months. The Malvern, PA-based company plans to list on the NASDAQ under the symbol TLOG. Oppenheimer & Co., Guggenheim Securities and Needham & Co. are the joint bookrunners on the deal.

Trevena (NASDAQ:TRVN), a clinical-stage biotech developing treatments for pain and acute heart failure, plans to raise $75 million by offering 5.8 million shares at a price range of $12.00 to $14.00. At the midpoint of the proposed range, Trevena would command a market value of $291 million. Trevena, which was founded in 2007, booked $0 million in sales over the last 12 months. The King of Prussia, PA-based company plans to list on the NASDAQ under the symbol TRVN. Barclays and Jefferies & Co. are the joint bookrunners on the deal.

Vince (NYSE:VNCE), which designs high-end apparel known for simple styling and luxurious materials, plans to raise $180 million by offering 10.0 million shares at a price range of $17.00 to $19.00. At the midpoint of the proposed range, Vince would command a market value of $683 million. Vince, which was founded in 2001, booked $264 million in sales over the last 12 months. The New York, NY-based company plans to list on the NYSE under the symbol VNCE. Goldman Sachs, Baird, BofA Merrill Lynch and Barclays are the joint bookrunners on the deal.

Vital Therapies (NASDAQ:VTL), a clinical-stage biotech developing treatments for acute liver failure, plans to raise $75 million by offering 4.4 million shares at a price range of $16.00 to $18.00. At the midpoint of the proposed range, Vital Therapies would command a market value of $277 million. Vital Therapies, which was founded in 2003, booked $0 million in sales over the last 12 months. The San Diego, CA-based company plans to list on the NASDAQ under the symbol VTL. Credit Suisse and William Blair are the joint bookrunners on the deal.

Last week, there were 8 IPO pricings. zulily (NASDAQ:ZU), a flash sales site offering deals on children's apparel and other products for moms, was the week's winner, ending up 71% from its IPO price.

Source: 10 U.S. IPOs Planned For The Week Of Nov. 18